SCHEMBL758845

SCHEMBL758845

Nc1cccc(-c2nc3ccccc3[nH]2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 1.00
KDM4E B2RXH2 11/20 1.00
SMN1; SMN2 Q16637 10/20 1.00
NPC1 O15118 10/20 1.00
RAB9A P51151 10/20 1.00
HPGD P15428 9/20 1.00
TP53 P04637 5/20 1.00
HSD17B10 Q99714 5/20 1.00
MAPT P10636 7/20 0.76
USP2 O75604 3/20 0.76
TDP1 Q9NUW8 2/20 0.76
PRMT1 Q99873 1/20 0.74
MEN1 O00255 5/20 0.69
KMT2A Q03164 5/20 0.69
POLB P06746 4/20 0.69
GAA P10253 3/20 0.69
BLM P54132 2/20 0.69
PKM P14618 6/20 0.68
GFER P55789 3/20 0.68
HTT P42858 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31063849 1.00 ALDH1A1 (1.00) ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL3417301 0.88 NPC1 (0.78) ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL9767339 0.87 MEN1 (0.90) ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL9767334 0.87 ALDH1A1 (0.77) ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL29906364 0.87 ALDH1A1 (0.77) ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL29596534 0.87 ALDH1A1 (0.77) ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL29377327 0.87 MEN1 (0.90) ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL21772077 0.86 ALDH1A1 (1.00) ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL6260440 0.86 ALDH1A1 (0.93) ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL28027557 0.86 KDM4E (0.75) ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115477615-B N- (3- (benzimidazol-2-yl) phenyl) amide compound and preparation method and application thereof 黄山学院 2024-06-18 CN claimed
CN-111808306-B Polyimide film with low thermal expansion coefficient and preparation method thereof 浙江中科玖源新材料有限公司 2023-04-07 CN claimed
CN-115477615-A N- (3- (benzimidazole-2-yl) phenyl) amide compound and preparation method and application thereof 黄山学院 2022-12-16 CN claimed
CN-111808306-A Polyimide film with low thermal expansion coefficient and preparation method thereof 浙江中科玖源新材料有限公司 2020-10-23 CN claimed
CN-122010934-A Pyrido [1,2-a ] pyrimidine mesoionic derivative containing amide structure, and preparation method and application thereof 贵州大学 2026-05-12 CN disclosed
EP-4559908-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF S2CBio Inc. (KR) 2025-05-28 EP disclosed
CN-115477615-B N- (3- (benzimidazol-2-yl) phenyl) amide compound and preparation method and application thereof 黄山学院 2024-06-18 CN disclosed
CN-115477615-B N- (3- (benzimidazol-2-yl) phenyl) amide compound and preparation method and application thereof 黄山学院 2024-06-18 CN disclosed
CN-115477615-B N- (3- (benzimidazol-2-yl) phenyl) amide compound and preparation method and application thereof 黄山学院 2024-06-18 CN disclosed
WO-2024058617-A1 ANTIVIRAL USE OF HETEROARYL DERIVATIVE COMPOUND 일동제약(주) 2024-03-21 WO disclosed
WO-2024019541-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF 일동제약(주) 2024-01-25 WO disclosed
WO-2024019541-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF 일동제약(주) 2024-01-25 WO disclosed
WO-2005030206-A1 ARYL-1,3-AZOLE DERIVATIVES AND METHODS FOR INHIBITING HEPARNASE ACTIVITY IMCLONE SYSTEMS INCORPORATED (US) 2005-04-07 WO disclosed
EP-1509499-A1 PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES GLAXO GROUP LIMITED (GB) 2005-03-02 EP disclosed
US-6858739-B2 Indole and benzimidazole 15-lipoxygenase inhibitors WARNER-LAMBERT COMPANY (US) 2005-02-22 US disclosed
US-20040038943-A1 Indole and benzimidazole 15-lipoxygenase inhibitors CONNOR DAVID THOMAS (US) 2004-02-26 US disclosed
WO-2003101959-A1 PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES GLAXO GROUP LIMITED (GB) 2003-12-11 WO disclosed
EP-1294686-A2 INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2003-03-26 EP disclosed
WO-2001096299-A2 INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-12-20 WO disclosed
EP-0226016-A1 Process for inhibiting hydrogen-induced corrosion of metallic materials BAYER AG (DE) 1987-06-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038943-A1 Indole and benzimidazole 15-lipoxygenase inhibitors ALOX15, ALOX5, ALOX12 ALDH1A1 470/4885KDM4E 881/4885SMN1; SMN2 4475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.